HHS' "Overly Broad" Identifier List Would Impede Research Data Flow - HIMA
This article was originally published in The Gray Sheet
Executive Summary
Omission of all identifiers specified in HHS' proposed "Standards for Privacy of Individually Identifiable Health Information" would yield "information that is useless for most research purposes," the Health Industry Manufacturers Association maintains in comments submitted to the department Feb. 17.
You may also be interested in...
HHS Moving Forward With Individual Health Care Data Privacy Standards
Knowledge and malicious misuse of unique health identifiers and individually identifiable health information could result in proposed penalties as severe as a $250,000 fine and ten years imprisonment, Health Care Financing Administration Director of Enterprise Standards, John Parmigiani said July 27.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.